Form SCHEDULE 13G/A Krystal Biotech, Inc. Filed by: Krishnan Krish S

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Krish S. Krishnan

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,388,283.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,388,283.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,388,283.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Suma M. Krishnan

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,388,283.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,388,283.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,388,283.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Krystal Biotech, Inc. (the "Company")

(b)

Address of issuer's principal executive offices:

2100 Wharton Street, Suite 701, Pittsburgh, Pennsylvania, 15203

Item 2.

(a)

Name of person filing:

The Reporting Persons, Mr. Krish S. Krishnan and his wife, Mrs. Suma M. Krishnan, each filed a Schedule 13G on April 4, 2018, which were both then amended on February 19, 2019, and February 14, 2020 (the "Individual 13Gs"). The Reporting Persons are now reporting together on this Schedule 13G/A, which is deemed to be the 3rd Amendment to the Individual 13Gs.

(b)

Address or principal business office or, if none, residence:

c/o KRYSTAL BIOTECH, INC. 2100 WHARTON STREET SUITE 701 PITTSBURGH, PA 15203

(c)

Citizenship:

Mr. and Mrs. Krishnan are citizens of the United States of America.

(d)

Title of class of securities:

Common Stock, $0.00001 par value ("Common Stock")

(e)

CUSIP No.:

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

Each of the Reporting Persons may be deemed to be the beneficial owner of an aggregate 3,388,283 shares of the Company's Common Stock as set forth in more detail in response to Item 4(c) below.

(b)

Percent of class:

11.5% The percentage was calculated in accordance with Rule 13d-3(d)(1)(i) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act") based on an aggregate total of 29,479,756 shares of Common Stock outstanding as of April 29, 2026, as reported by the Company in its Form 10-Q filed with the U.S. Securities and Exchange Commission on May 4, 2026. %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Krish S. Krishnan: 0 shares of Common Stock Suma M. Krishnan: 0 shares of Common Stock

(ii) Shared power to vote or to direct the vote:

Krish S. Krishnan: 3,388,283 shares of Common Stock Suma M. Krishnan: 3,388,283 shares of Common Stock The reported securities are directly held as follows: (i) 1,475,253 shares of Common Stock directly owned by Krish S. Krishnan; (ii) 1,403,155 shares of Common Stock directly owned by Suma M. Krishnan; (iii) 90,000 shares of Common Stock that are directly owned by the SMK Trust FBO KSK, an irrevocable trust established by Mrs. Krishnan for the benefit of Mr. Krishnan who serves as a co-trustee and shares voting and dispositive power with a 3rd party co-trustee. These shares of Common Stock are not beneficially owned by Mrs. Krishnan but are included to disclose the aggregate holdings of both Reporting Persons; (iv) 90,000 shares of Common Stock that are directly owned by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and dispositive power with a 3rd party co-trustee. These shares of Common Stock are not beneficially owned by Mr. Krishnan but are included to disclose the aggregate holdings of both Reporting Persons; (v) 50,000 shares of Common Stock owned by the Krishnan Family Trust, a revocable trust established for the benefit of Mr. and Mrs. Krishnan who share voting and investment control of the trust; (v) 158,525 shares of Common Stock issuable upon the exercise of stock options held by Mr. Krishnan; and (vi) 121,350 shares of Common Stock issuable upon the exercise of stock options held by Mrs. Krishnan. The Reporting Persons may be deemed to share beneficial ownership of the reported securities, but the filing of this Statement shall not be construed as an admission of such beneficial ownership for purposes of Section 13(d) or 13(g) of the Exchange Act or for any other purpose.

(iii) Sole power to dispose or to direct the disposition of:

Krish S. Krishnan: 0 shares of Common Stock Suma M. Krishnan: 0 shares of Common Stock

(iv) Shared power to dispose or to direct the disposition of:

Krish S. Krishnan: 3,388,283 shares of Common Stock Suma M. Krishnan: 3,388,283 shares of Common Stock See Item 4(c)(ii) above, which is incorporated herein by reference.

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Krish S. Krishnan

Signature:	/s/ Krish S. Krishnan
Name/Title:	Krish S. Krishnan/Chariman & CEO
Date:	05/04/2026

Suma M. Krishnan

Signature:	/s/Suma M. Krishnan
Name/Title:	Suma M. Krishnan/Director, President R&D
Date:	05/04/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement

Form SCHEDULE 13G/A Krystal Biotech, Inc. Filed by: Krishnan Krish S

You May Also Be Interested In

Create E-mail Alert Related Categories

Related Entities

Sign up for StreetInsider Free!

Free News Feed